Crossmark

Risk factors and outcome of Stenotrophomonas maltophilia infection after allogeneic hematopoietic stem cell transplantation: JSTCT, Transplant Complications Working Group

Crossref DOI link: https://doi.org/10.1007/s00277-023-05320-4

Published Online: 2023-06-20

Published Print: 2023-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Saburi, Masuho https://orcid.org/0000-0001-6097-5633
Oshima, Kumi

Takano, Kuniko

Inoue, Yoshitaka

Harada, Kaito

Uchida, Naoyuki

Fukuda, Takahiro

Doki, Noriko

Ikegame, Kazuhiro

Matsuo, Yayoi

Katayama, Yuta

Ozawa, Yukiyasu

Matsuoka, Ken-ichi

Kawakita, Toshiro

Mori, Yasuo

Ara, Takahide

Nakamae, Hirohisa

Kimura, Takafumi

Kanda, Yoshinobu

Atsuta, Yoshiko

Ogata, Masao

,
License Information

Text and Data Mining valid from 2023-06-20

Version of Record valid from 2023-06-20
More Information

Article History

Received: 28 January 2023

Accepted: 12 June 2023

First Online: 20 June 2023

Declarations

:

: HN reports Grants or contracts from Novartis, Astellas, Otsuka, Alexion, PPD-SNBL, Cmic, Meiji Seika, and Bristol-Myers Squibb; Consulting fees from Ono, Simon-Kucher & Partners, Daiichi Sankyo, and Novartis; Payment or honoraria (e.g., lecture fees) from Astellas, Otsuka, Sumitomo Dainippon, Takeda, Novartis, Bristol-Myers Squibb, Nippon Shinyaku, Astellas-Amgen, Shire, Celgene, Daiichi Sankyo, and Pfizer. ND reports Payment from Novartis Pharma and Janssen Pharma. The other authors declare no competing interests associated with this paper.

Document is current

Any future updates will be listed below